JPWO2020158607A1 - - Google Patents

Info

Publication number
JPWO2020158607A1
JPWO2020158607A1 JP2020569584A JP2020569584A JPWO2020158607A1 JP WO2020158607 A1 JPWO2020158607 A1 JP WO2020158607A1 JP 2020569584 A JP2020569584 A JP 2020569584A JP 2020569584 A JP2020569584 A JP 2020569584A JP WO2020158607 A1 JPWO2020158607 A1 JP WO2020158607A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020569584A
Other languages
Japanese (ja)
Other versions
JP7497880B2 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2020158607A1 publication Critical patent/JPWO2020158607A1/ja
Application granted granted Critical
Publication of JP7497880B2 publication Critical patent/JP7497880B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/32Manganese; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/337Polymers modified by chemical after-treatment with organic compounds containing other elements

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020569584A 2019-01-29 2020-01-24 Hydrophilic polymer crosslinked network hydrogel and active oxygen inhibitor Active JP7497880B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019013296 2019-01-29
JP2019013296 2019-01-29
PCT/JP2020/002541 WO2020158607A1 (en) 2019-01-29 2020-01-24 Hydrophilic polymer crosslinked network hydrogel and active oxygen inhibitor

Publications (2)

Publication Number Publication Date
JPWO2020158607A1 true JPWO2020158607A1 (en) 2020-08-06
JP7497880B2 JP7497880B2 (en) 2024-06-11

Family

ID=71839984

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020569584A Active JP7497880B2 (en) 2019-01-29 2020-01-24 Hydrophilic polymer crosslinked network hydrogel and active oxygen inhibitor

Country Status (2)

Country Link
JP (1) JP7497880B2 (en)
WO (1) WO2020158607A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022056880A1 (en) * 2020-09-18 2022-03-24 Chongqing University Ros-responsive nanocarrier, preparation and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170050996A1 (en) * 2015-08-18 2017-02-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Antioxidant compounds and their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4824911B2 (en) * 2004-01-30 2011-11-30 一般財団法人川村理化学研究所 Hydrogel, cross-linked hydrogel and method for producing them
JP5745415B2 (en) * 2009-09-17 2015-07-08 国立大学法人九州大学 Porphyrin compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170050996A1 (en) * 2015-08-18 2017-02-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Antioxidant compounds and their use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEUNG Y. CHARLES ET AL.: "Synthesis of Polymerizable Superoxide Dismutase Mimetics to Reduce Reactive Oxygen Species Damage in", ADVANCED FUNCTIONAL MATERIALS, vol. Volume 18, Issue 20, JPN6020009414, 6 October 2008 (2008-10-06), pages 3119 - 3126, ISSN: 0005082384 *
LOVELL F. JONATHAN ET AL.: "Porphyrin-Cross-Linked Hydrogel for Fluorescence-Guided Monitoring and Surgical Resection", BIOMACROMOLECULES, vol. Volume 12, Issue 9, JPN6020009413, 21 July 2011 (2011-07-21), pages 3115 - 3118, ISSN: 0005082383 *

Also Published As

Publication number Publication date
WO2020158607A1 (en) 2020-08-06
JP7497880B2 (en) 2024-06-11

Similar Documents

Publication Publication Date Title
BR112021017339A2 (en)
BR112021013854A2 (en)
BR112021018450A2 (en)
BR112021017939A2 (en)
BR112021017892A2 (en)
BR112021017738A2 (en)
BR112021017782A2 (en)
BR112021018168A2 (en)
BR112021017728A2 (en)
BR112021018452A2 (en)
BR112021017234A2 (en)
BR112021017355A2 (en)
BR112021017703A2 (en)
BR112021017173A2 (en)
BR112021018102A2 (en)
BR112021017083A2 (en)
BR112021017637A2 (en)
BR112021018250A2 (en)
BR112021018084A2 (en)
BR112021018093A2 (en)
BR112021013944A2 (en)
BR112021018484A2 (en)
BR112021017732A2 (en)
BR112021015080A2 (en)
BR112021017949A2 (en)

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A5211

Effective date: 20210318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240312

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240521

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240523

R150 Certificate of patent or registration of utility model

Ref document number: 7497880

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150